Brufen Akut Duo Visual Identity

Viatris introduces "BRUFEN AKUT DUO" within the Brufen product line, a novel combination of Ibuprofen 200 mg and Paracetamol 500 mg.

Brufen Akut Duo Visual Identity

Powerful Fusion: Crafting BRUFEN AKUT DUO's Visual Identity

We were tasked to create a visual identity to enhance the brand image that reflected the product's dual-action promise and positioned it as the preferred choice for pharmacists, healthcare professionals, and patients.

Brufen Akut Duo Visual Identity

Within the Brufen product line, Viatris has introduced a novel offering known as "BRUFEN AKUT DUO." This product combines Ibuprofen 200 mg with Paracetamol 500 mg. The utilisation of combination therapy is typically recommended when the pain is not relieved with either Ibuprofen or Paracetamol as standalone treatments. The objective was to create a visual identity that not only aligns with the brand's promise of double action and strengthens the position of the brand in the market but also makes it a brand of choice for pharmacists, HCPs, and patients in the Albanian OTC market. 



Emphasising the dual efficacy of Ibuprofen and Paracetamol of BRUFEN AKUT DUO's our concept for the visual identity encompasses a clean and uncluttered design philosophy. We conceptualised a visual identity that featured a rocket with two powerful engines, representing Ibuprofen and Paracetamol in BRUFEN AKUT DUO. These dual engines symbolise the unique and complementary actions of the molecules working together for enhanced pain relief. The rocket targets a pain symbol crafted from clouds. The tagline, "Double Action for Relief from Pain and Fever," highlights complementary actions provided by BRUFEN AKUT DUO.​



We successfully created a strong visual identity for BRUFEN AKUT DUO, which effectively communicated the brand’s USPs and helped it strengthen its base in the Albanian OTC market. Through the visual identity, BRUFEN AKUT DUO became a preferred brand of choice among pharmacists and HCPs and continued the growth and positioning of BRUFEN AKUT DUO among analgesics and anti-inflammatory drugs.​


Other Casestudies